SSY Group (HK:2005) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
SSY Group Limited has successfully obtained approval from China’s National Medical Products Administration for its drug Nikethamide, a central nervous system stimulant used to treat respiratory depression. This development marks a significant step for the company as it enhances its product portfolio in the pharmaceutical market.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.
